Ramsay Santé
Pascal Roché has extensive work experience in various high-level roles within the finance and healthcare industries. Pascal started their career at Mars & Co. as a Director of Studies in 1985. Pascal then moved on to AXA en France, where they served as Deputy General Director for AXA France Services and later as Director of Strategy and Internal Control. In 2002, they joined Barclays as the CEO for France and then for Spain. Since 2011, Roché has been serving as the CEO of Ramsay Santé. Rocé's roles throughout their career highlight their strong leadership skills and their ability to successfully manage large organizations.
Pascal Roché attended HEC Paris, a renowned institution, but it is not clear when they started or completed their education there. Following their time at HEC Paris, they pursued further studies at Paris-Pantheon-Assas University, where they obtained a Maîtrise degree in Droit Privé in 1985. Additionally, they were enrolled at Université Paris Dauphine - PSL in the same year, completing their studies with a DEA degree in Économie et Stratégie des Organisations. The exact duration of their education at these universities is unknown.
This person is not in any offices
Ramsay Santé
1 followers
After the acquisition of the Capio Group in 2018, Ramsay Santé has become Europe's leading private hospital and primary care companies. The group now has 36,000 employees and works with nearly 8,600 private practitioners. Present in 5 countries, France, Sweden, Norway, Denmark and Italy, the group treats more than 7 million patients per year in its 350 establishments. In hospitalization, Ramsay Santé offers almost all medical and surgical treatments in three business lines: Medicine-Surgery-Obstetrics (MCO), Follow-up and Rehabilitation Care (SSR) and Mental Health. Wherever it is present, the group participates in public health service missions and in the health network of the country, as in Sweden where the group has more than a hundred local health centres. The quality and safety of care is the group's priority in all the countries where it operates. This is why the group is today one of the references in modern medicine, especially in ambulatory surgery and enhanced recovery after surgery (ARS). The group also invests more than €200 million every year in its establishments, whether in new surgical and imaging technologies, or in the construction and modernisation of establishments. It also innovates at the service of patients with new digital tools and by developing its organisations to improve the efficiency of care.